Cybin

Cybin is a clinical-stage biopharmaceutical company focused on developing psychedelic-based therapeutics for mental health conditions. The company is advancing CYB003, a proprietary deuterated psilocybin analog, for the treatment of major depressive disorder (MDD). CYB003 has received FDA Breakthrough Therapy Designation for the adjunctive treatment of MDD and has shown positive Phase 2 interim data, demonstrating rapid and significant improvements in depression symptoms after a single dose. The composition of matter patent for CYB003 provides protection through 2041. Cybin is also developing CYB004, a deuterated dimethyltryptamine (dDMT) molecule, for the treatment of generalized anxiety disorder (GAD). CYB004 has demonstrated improved bioavailability and pharmacokinetic profile in preclinical studies compared to DMT. Cybin has completed dosing in its Phase 2 study of CYB003 for MDD, with topline efficacy data expected in Q4 2023, and is preparing for a potential Phase 3 study in early 2024. The company has developed EMBARK, a model of psychedelic facilitation training to support clinical trials, and has partnered with Worldwide Clinical Trials to manage clinical trials for mental health conditions, including MDD. Cybin has more than 50 granted or pending patent applications filed across 6 patent families and has completed over 250 pre-clinical studies. The company’s proprietary delivery systems aim to provide fast onset of action, better control of dosing, short duration, low variability, reduced side effects, and less invasive dosing methods. Cybin operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.